Literature DB >> 27922501

An Overview of Congenital Myopathies.

Jean K Mah, Jeffrey T Joseph.   

Abstract

PURPOSE OF REVIEW: This article uses a case-based approach to highlight the clinical features as well as recent advances in molecular genetics, muscle imaging, and pathophysiology of the congenital myopathies. RECENT
FINDINGS: Congenital myopathies refer to a heterogeneous group of genetic neuromuscular disorders characterized by early-onset muscle weakness, hypotonia, and developmental delay. Congenital myopathies are further classified into core myopathies, centronuclear myopathies, nemaline myopathies, and congenital fiber-type disproportion based on the key pathologic features found in muscle biopsies. Genotype and phenotype correlations are hampered by the diverse clinical variability of the genes responsible for congenital myopathies, ranging from a severe neonatal course with early death to mildly affected adults with late-onset disease. An increasing number of genes have been identified, which, in turn, are associated with overlapping morphologic changes in the myofibers. Precise genetic diagnosis has important implications for disease management, including family counseling; avoidance of anesthetic-related muscle injury for at-risk individuals; monitoring for potential cardiac, respiratory, or orthopedic complications; as well as for participation in clinical trials or potential genetic therapies.
SUMMARY: Collaboration with neuromuscular experts, geneticists, neuroradiologists, neuropathologists, and other specialists is needed to ensure accurate and timely diagnosis based on clinical and pathologic features. An integrated multidisciplinary model of care based on expert-guided standards will improve quality of care and optimize outcomes for patients and families with congenital myopathies.

Entities:  

Mesh:

Year:  2016        PMID: 27922501     DOI: 10.1212/CON.0000000000000404

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  7 in total

1.  Congenital myopathies in the adult neuromuscular clinic: Diagnostic challenges and pitfalls.

Authors:  Stefan Nicolau; Teerin Liewluck; Jennifer A Tracy; Ruple S Laughlin; Margherita Milone
Journal:  Neurol Genet       Date:  2019-06-04

Review 2.  Update on Congenital Myopathies in Adulthood.

Authors:  George Konstantinos Papadimas; Sophia Xirou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

3.  Congenital fiber-type disproportion presenting with type II respiratory failure after delivery: A case report.

Authors:  Hong-Mei Yang; Jian-Xing Guo; Yi-Min Yang
Journal:  World J Clin Cases       Date:  2021-03-06       Impact factor: 1.337

4.  Phenotypic Variability of MEGF10 Variants Causing Congenital Myopathy: Report of Two Unrelated Patients from a Highly Consanguineous Population.

Authors:  Mohammad AlMuhaizea; Omar Dabbagh; Hanan AlQudairy; Aljouhra AlHargan; Wafa Alotaibi; Ruba Sami; Rahaf AlOtaibi; Mariam Mahmoud Ali; Hindi AlHindi; Dilek Colak; Namik Kaya
Journal:  Genes (Basel)       Date:  2021-11-10       Impact factor: 4.096

5.  Clinico-pathological features and mutational spectrum of 16 nemaline myopathy patients from a Chinese neuromuscular center.

Authors:  Xi Yin; Chuanqiang Pu; Zhenfu Wang; Ke Li; HuiFang Wang
Journal:  Acta Neurol Belg       Date:  2021-03-19       Impact factor: 2.471

6.  Sarcomeric myopathies associated with tremor: new insights and perspectives.

Authors:  Janis Stavusis; Janelle Geist; Aikaterini Kontrogianni-Konstantopoulos
Journal:  J Muscle Res Cell Motil       Date:  2019-10-16       Impact factor: 3.352

7.  Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings.

Authors:  Joshua J Todd; Muslima S Razaqyar; Jessica W Witherspoon; Tokunbor A Lawal; Ami Mankodi; Irene C Chrismer; Carolyn Allen; Mary D Meyer; Anna Kuo; Monique S Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G Bönnemann; James J Dowling; Katherine G Meilleur
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.